Disc Medicine To Present New Data From Phase 1b Trial Of DISC-0974 In Patients With Chronic Kidney Disease And Anemia At 2024 American Society Of Nephrology Kidney Week
Portfolio Pulse from Benzinga Newsdesk
Disc Medicine is set to present new data from its Phase 1b trial of DISC-0974, a treatment for chronic kidney disease and anemia, at the 2024 American Society of Nephrology Kidney Week.
October 11, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Disc Medicine will present new data on DISC-0974, a potential treatment for chronic kidney disease and anemia, at a major nephrology conference.
The presentation of new data from a Phase 1b trial at a major conference could positively impact Disc Medicine's stock by increasing investor confidence in DISC-0974's potential. This is a significant step in the drug's development process.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90